Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports

BACKGROUND: Nafamostat mesylate (NM) may prove to be one of the key drugs effective against coronavirus disease 2019 (COVID-19) because of its anti-viral properties and the potential to manage coagulopathy. However, NM tends to increase serum potassium levels. CASE SUMMARY: We observed hyperkalemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Okajima, Masaki, Takahashi, Yoshinori, Kaji, Takaaki, Ogawa, Naohiko, Mouri, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674713/
https://www.ncbi.nlm.nih.gov/pubmed/33269265
http://dx.doi.org/10.12998/wjcc.v8.i21.5320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674713/
https://www.ncbi.nlm.nih.gov/pubmed/33269265
http://dx.doi.org/10.12998/wjcc.v8.i21.5320

Ejemplares similares